<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3940">
  <stage>Registered</stage>
  <submitdate>7/08/2012</submitdate>
  <approvaldate>7/08/2012</approvaldate>
  <nctid>NCT01663896</nctid>
  <trial_identification>
    <studytitle>Observational Study of Optical Coherence Tomography (OCT) in Patients Undergoing Fractional Flow Reserve (FFR) and Percutaneous Coronary Intervention</studytitle>
    <scientifictitle>Observational Study of Optical Coherence Tomography (OCT) in Patients Undergoing Fractional Flow Reserve (FFR) and Percutaneous Coronary Intervention Stage I (ILUMIEN I)</scientifictitle>
    <utrn />
    <trialacronym>ILUMIEN I</trialacronym>
    <secondaryid>SJM-CVD-0612</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Single or Multi Vessel Disease</healthcondition>
  </conditions>
  <interventions>
    <interventions>Single or multi vessel disease - 

</interventions>
    <comparator />
    <control />
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Identify OCT peri-procedural guidance parameter(s) for stent implantation that relates with patient outcomes in the hospital, at 30 days, and 12 months post intervention.</outcome>
      <timepoint>participants will be followed from their hospital stay until 12 months after</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Correlation/relationship of OCT parameters, as defined by OCT volumetric analysis, on pre and post intervention FFR values.</outcome>
      <timepoint>participants will be followed from their hospital stay until 12 months after</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Consideration of health economics data and resource utilization.</outcome>
      <timepoint>participants will be followed from their hospital stay until 12 months after</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Age = 18 years.

          2. Patient provides signed written informed consent before any study-specific procedure.

          3. De novo coronary artery disease in target vessel.

          4. Single or multi vessel disease. For multi vessel disease up to two vessels and three
             lesions treated, with no more than two lesions per vessel. Vessel is defined as, left
             anterior descending, left circumflex, and right coronary arteries. Any branch within
             the vessel is considered part of the vessel.

          5. Elective or ad hoc PCI, stable angina, acute coronary syndrome (unstable angina and
             NSTEMI).

          6. Angiographically significant (&gt;50% visual estimation) stenosis present in at least one
             native coronary artery.

          7. Mandatory use of FFR and OCT pre and post PCI. PCI strongly recommended in subjects
             with an FFR = 0.80 in target vessel.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Subjects with STEMI, emergent PCI, or in cardiogenic shock.

          2. Subjects with target left main lesion.

          3. Subjects with restenosis or stent thrombosis in the target vessel.

          4. Planned use of bare metal stent.

          5. Known renal insufficiency (examples being but not limited to eGFR &lt; 60 ml/kg/m2, serum
             creatinine = 2.5 mg/dL, or on dialysis).

          6. Aorto-ostial lesion location within 3 mm of the aorta junction (both right and left).

          7. Extreme angulation (&gt; 90°) or excessive tortuosity (&gt; two 45° angles) proximal to or
             within the target lesion.

          8. Vessel(s) and lesion(s) not amenable for PCI, for example diffuse disease.

          9. Any other medical condition that in the opinion of the investigator will interfere
             with patient safety or study results.

         10. Currently participating in another clinical study that interferes with study results.

         11. Pregnant or nursing subjects and those who plan pregnancy in the period up to 1 year
             following index procedure.

         12. Life expectancy less than 1 year.

         13. Potential for non-compliance to protocol requirements and follow-up.

         14. Planned or prior heart transplantation or listed for heart transplant.

         15. Any condition that precludes the subject from undergoing PCI, for example subjects
             with heparin induced thrombocytopenia, or contrast allergy.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/11/2012</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>418</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/10/2015</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>QLD</recruitmentstate>
    <hospital>The Prince Charles Hospital - Chermside</hospital>
    <postcode> - Chermside</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Alabama</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kentucky</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Wisconsin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Vienna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Aalst</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Leuven</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Hong Kong</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Brno</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Clermont-Ferrand</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Le Plessis Robinson</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Toulouse</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Munich</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Bergamo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Milan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Rome</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Hyogo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Nara</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Osaka</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Wakayama</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Rotterdam</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>St. Jude Medical</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>To define and evaluate OCT stent guidance parameters through prospective data collection in
      PCI procedures of de novo lesions.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01663896</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>